Treatment of hypertrophic obstructive cardiomyopathy with verapamil.

M Kaltenbach, R Hopf, G Kober, W D Bussmann, M Keller, Y Petersen

Twenty-two patients with hypertrophic obstructive cardiomyopathy were treated with the calcium inhibitor, verapamil, which was administered in a mean oral dose of 480 mg per day. After an average of 15 months of treatment (4 to 24 months), the QRS amplitude in the electrocardiogram was significantly reduced from 4.2 to 3.8 mV. Heart volume calculated from chest x-ray films in the supine position decreased significantly from 858 to 766 ml per 1.73 m2. In 10 patients, follow-up heart catheterisation showed a decrease in left ventricular muscle mass in 7 patients and a slight increase in 3 patients. Coronary artery diameter decreased in 7 patients, increased in 1, and was unchanged in 2. The reduction in coronary artery diameter is considered to be a consequence of a reduced heart muscle mass. From all available clinical data it is concluded that verapamil treatment is superior to beta-blocker therapy.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Fifer, M. A., Vlahakes, G. J. (2008). Management of Symptoms in Hypertrophic Cardiomyopathy. Circulation 117: 429-439 [Full Text]  
• Thaman, R., Gimeno, J. R., Reith, S., Esteban, M. T. T., Limongelli, G., Murphy, R. T., Mist, B., McKenna, W. J., Elliott, P. M. (2004). Progressive left ventricular remodeling in patients with hypertrophic cardiomyopathy and severe left ventricular hypertrophy. J Am Coll Cardiol 44: 398-405 [Abstract] [Full Text]  
• Maron, B. J., McKenna, W. J., Danielson, G. K., Kappenberger, L. J., Kuhn, H. J., Seidman, C. E., Shah, P. M., Spencer, W. H. III, Spirito, P., Ten Cate, F. J., Wigle, E. D., Vogel, R. A., Abrams, J., Bates, E. R., Brodie, B. R., Danias, P. G., Gregoratos, G., Hlatky, M. A., Hochman, J. S., Kaul, S., Lichtenberg, R. C., Lindner, J. R., O'rourke, R. A., Pohost, G. M., Schofield, R. S., Tracy, C. M., Winters, W. L. Jr, Klein, W. W., Priori, S. G., Alonso-Garcia, A., Blomstrom-Lundqvist, C., De Backer, G., Deckers, J., Flather, M., Hradec, J., Oto, A., Parkhomenko, A., Silber, S., Torbicki, A. (2003). American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 42: 1687-1713 [Full Text]  
• Writing Committee Members, , Maron, B. J., McKenna, W. J., Danielson, G. K., Kappenberger, L. J., Kuhn, H. J., Seidman, C. E., Shah, P. M., Spencer, W. H. III, Spirito, P., Ten Cate, F. J., Wigle, E. D., ACCF Task Force on Clinical Expert Consensus Docum, , Vogel, R. A., Abrams, J., Bates, E. R., Brodie, B. R., Danias, P. G., Gregoratos, G., Hlatky, M. A., Hochman, J. S., Kaul, S., Lichtenberg, R. C., Lindner, J. R., O'Rourke, R. A., Pohost, G. M., Schofield, R. S., Tracy, C. M., Winters, W. L. Jr, ESC Committee for Practice Guidelines Members, , Klein, W. W., Priori, S. G., Alonso-Garcia, A., Blomstrom-Lundqvist, C., De Backer, G., Deckers, J., Flather, M., Hradec, J., Oto, A., Parkhomenko, A., Silber, S., Torbicki, A. (2003). American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy: A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. Eur Heart J 24: 1965-1991 [Full Text]  
• Ryden, L., Gadler, F. (2001). Pharmacological therapy for hypertrophic cardiomyopathy: what is the evidence for success?. Eur Heart J Suppl 3: L21-L25 [Abstract]  
• Hamada, M., Shigematsu, Y., Ikeda, S., Hara, Y., Okayama, H., Kodama, K., Ochi, T., Hiwada, K. (1997). Class Ia Antiarrhythmic Drug Cibenzoline : A New Approach to the Medical Treatment of Hypertrophic Obstructive Cardiomyopathy. Circulation 96: 1520-1524 [Abstract] [Full Text]  
• Hartmann, A., Schnell, J., Hopf, R., Kneissl, G. (1996). Persisting Effect of Ca2+-Channel Blockers on Left Ventricular Function in Hypertrophic Cardiomyopathy After 14 Years' Treatment. ANGIOLOGY 47: 765-773 [Abstract]  
• Schoendube, F. A., Klues, H. G., Reith, S., Flachskampf, F. A., Hanrath, P., Messmer, B. J. (1995). Long-term Clinical and Echocardiographic Follow-up After Surgical Correction of Hypertrophic Obstructive Cardiomyopathy With Extended Myectomy and Reconstruction of the Subvalvular Mitral Apparatus. Circulation 92: 122-127 [Abstract] [Full Text]  
• Wigle, E. D., Rakowski, H., Kimball, B. P., Williams, W. G. (1995). Hypertrophic Cardiomyopathy : Clinical Spectrum and Treatment. Circulation 92: 1680-1692 [Full Text]  
• Baughman, K. L. (1992). Hypertrophic Cardiomyopathy. JAMA 267: 846-849 [Abstract]  
• Cho, C., Pruitt, A. W., Corrigan, J. J. Jr, Allen, H. D., Hong, R., Kisker, C. T. (1986). Therapeutic Uses of Calcium Channel-Blocking Drugs in the Young. Arch Pediatr Adolesc Med 140: 360-366 [Abstract]  
• Morris, D. L., Goldschlager, N. (1983). Calcium Infusion for Reversal of Adverse Effects of Intravenous Verapamil. JAMA 249: 3212-3213 [Abstract]  
• Winniford, M. D., Willerson, J. T., Hillis, L. D. (1982). Calcium Antagonists in the Treatment of Individuals with Ischemic Heart Disease. ANGIOLOGY 33: 522-539 [Abstract]  
• ROSING, D. R., EPSTEIN, S. E. (1982). Verapamil in the Treatment of Hypertrophic Cardiomyopathy. ANN INTERN MED 96: 670-672 [Abstract]  
• STONE, P. H., ANTMAN, E. M., MULLER, J. E., BRAUNWALD, E. (1980). Calcium Channel Blocking Agents in the Treatment of Cardiovascular Disorders. Part II: Hemodynamic Effects and Clinical Applications. ANN INTERN MED 93: 886-904 [Abstract]